Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography

PLoS One. 2013 May 24;8(5):e63705. doi: 10.1371/journal.pone.0063705. Print 2013.

Abstract

Objectives: Pemetrexed is a thymidylate synthase (TS) inhibitor and is effective in non-small cell lung cancer (NSCLC). 3'-deoxy-3'-[¹⁸F]fluorothymidine (¹⁸F-FLT), a proliferation marker, could potentially identify tumor specific TS-inhibition. The aim of this study was to investigate the effect of pemetrexed-induced TS-inhibition on ¹⁸F-FLT uptake 4 hours after pemetrexed administration in metastatic NSCLC patients.

Methods: Fourteen NSCLC patients underwent dynamic ¹⁸F-FLT positron emission tomography (PET) scans at baseline and 4 hours after the first dose of pemetrexed. Volumes of interest were defined with a 41%, 50% and 70% threshold of the maximum pixel. Kinetic analysis and simplified measures were performed. At one, two, four and six hours after pemetrexed, plasma deoxyuridine was measured as systemic indicator of TS-inhibition. Tumor response measured with response evaluation criteria in solid tumors (RECIST), time to progression (TTP) and overall survival (OS) were determined.

Results: Eleven patients had evaluable ¹⁸F-FLT PET scans at baseline and 4 hours after pemetrexed. Two patients had increased ¹⁸F-FLT uptake of 35% and 31% after pemetrexed, whereas two other patients had decreased uptake of 31%. In the remaining seven patients ¹⁸F-FLT uptake did not change beyond test-retest borders. In all patients deoxyuridine levels raised after administration of pemetrexed, implicating pemetrexed-induced TS-inhibition. ¹⁸F-FLT uptake in bone marrow was significantly increased 4 hours after pemetrexed administration. Six weeks after the start of treatment 5 patients had partial response, 4 stable disease and 2 progressive disease. Median TTP was 4.2 months (range 3.0-7.4 months); median OS was 13.0 months (range 5.1-30.8 months). Changes in ¹⁸F-FLT uptake were not predictive for tumor response, TTP or OS.

Conclusions: Measuring TS-inhibition in a clinical setting 4 hours after pemetrexed revealed a non-systematic change in ¹⁸F-FLT uptake within the tumor. No significant association with tumor response, TTP or OS was observed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / pharmacology*
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging*
  • Carcinoma, Non-Small-Cell Lung / metabolism*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Deoxyuridine / blood
  • Deoxyuridine / metabolism
  • Dideoxynucleosides / pharmacokinetics
  • Female
  • Glutamates / administration & dosage
  • Glutamates / pharmacology*
  • Guanine / administration & dosage
  • Guanine / analogs & derivatives*
  • Guanine / pharmacology
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics
  • Methylenetetrahydrofolate Reductase (NADPH2) / metabolism
  • Middle Aged
  • Neoplasm Metastasis
  • Outcome Assessment, Health Care
  • Pemetrexed
  • Polymorphism, Genetic
  • Positron-Emission Tomography*
  • Prognosis
  • Thymidylate Synthase / antagonists & inhibitors*
  • Thymidylate Synthase / genetics
  • Thymidylate Synthase / metabolism
  • Time Factors
  • Tissue Distribution

Substances

  • Antimetabolites, Antineoplastic
  • Dideoxynucleosides
  • Glutamates
  • Pemetrexed
  • Guanine
  • MTHFR protein, human
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Thymidylate Synthase
  • alovudine
  • Deoxyuridine

Grants and funding

The authors acknowledge the Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy project (QuIC-ConCePT project) from the Innovative Medicines Initiative (IMI) for partly funding the project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.